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OBJECTIVES We sought to determine the incidence of and risk factors for the development of restenosis
and neointimal proliferation after endovascular stent implantation for congenital heart disease
(CHD).
BACKGROUND Risk factors for the development of restenosis and neointimal proliferation are poorly
understood.
METHODS This was a retrospective review of patients who underwent endovascular stent redilation
between September 1989 and February 2000.
RESULTS Of 368 patients who had 752 stents implanted, 220 were recatheterized. Of those 220
patients, 103 underwent stent redilation. Patients were classified into three groups: 1) those
with pulmonary artery stenosis (n 5 94), tetralogy of Fallot/pulmonary atresia (n 5 72),
congenital branch pulmonary stenosis (n 5 9), status post-Fontan operation (n 5 6), status
post-arterial switch operation (n 5 7); 2) those with iliofemoral venous obstruction (n 5 6);
and 3) those with miscellaneous disorders (n 5 3). The patients’ median age was 9.9 years
(range 0.5 to 39.8); their mean follow-up duration was 3.8 years (range 0.1 to 10). Indications
for stent redilation included somatic growth (n 5 67), serial dilation (n 5 27) and
development of neointimal proliferation or restenosis, or both (n 5 9). There was a low
incidence of neointimal proliferation (1.8%) and restenosis (2%). There were no deaths.
Complications included pulmonary edema (n 5 1), hemoptysis (n 5 1) and contralateral stent
compression (n 5 2).
CONCLUSIONS Redilation or further dilation of endovascular stents for CHD is effective as late as 10 years.
The risk of neointimal proliferation (1.8%) and restenosis (2%) is low and possibly avoidable.
Awareness of specific risk factors and modification of the stent implantation technique,
including avoidance of minimal stent overlap and sharp angulation of the stent to the vessel
wall and avoidance of overdilation, have helped to reduce the incidence of restenosis. (J Am
Coll Cardiol 2001;38:521–6) © 2001 by the American College of Cardiology
The first successful application of endovascular stents to
maintain vessel patency was reported by Dotter in 1969 (1).
Its use in children with congenital heart disease (CHD) was
first demonstrated in the early 1990s (2,3). Stents have been
used to treat pulmonary artery stenosis (congenital and
acquired) (3–5), coarctation of the aorta (6,7), systemic and
central venous obstructions (8), postoperative conditions,
including cavopulmonary communications and conduit/
homograft obstruction (9), as well as in attempts to main-
tain ductal patency (10). Initially, there were concerns about
the potential for stent restenosis and the ability with which
subsequent balloon dilation could be performed. One study
demonstrated a 3% rate of restenosis and neointimal pro-
liferation at a mean follow-up of 13 months (11). However,
the incidence of restenosis and neointimal proliferation at
intermediate- to long-term follow-up remains unanswered.
METHODS
We retrospectively analyzed all patients who underwent
redilation of endovascular stents (Palmaz Johnson & John-
son, Piscataway, New Jersey) between September 1989 and
February 2000. All of the patients’ demographic data were
studied (age, weight, gender, diagnosis, past surgical histo-
ry), including the interval from the first stent implant to the
time of redilation and subsequent redilations. Patients were
classified into one of three groups according to the location
of the stent implant. The cardiac catheterization data at the
initial stent implant and at redilation were examined to
determine the pressure gradient, lumen diameter, number
and dimension of stents initially implanted, reduction in the
pressure gradient (in appropriate cases expressed as the right
ventricle [RV] to femoral artery [FA] pressure ratio),
increase in vessel diameter and occurrence of complications.
Restenosis was defined as a reduction in the stent lumen
diameter less than the adjacent nominal vessel diameter or
development or increase in the pressure gradient across the
stent, or both.
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Neointimal proliferation was defined as a lining between
the stent and the lumen, as seen on the angiogram. Mild or
physiologic intimal hyperplasia was defined as ,1 mm on
either side of the stented vessel; moderate as 1 to 1.5 mm;
and severe as .1.5 mm.
Recatheterization. Our practice has been to recatheterize
patients one to three years after stent implantation, or when
their weight has increased sufficiently to have hemodynamic
consequences. Repeat catheterization is also indicated when
the adult’s weight is reached to achieve the full dilation
potential of the stented vessel.
Statistics. Comparisons of the pre-redilation and post-
redilation differences in the stent’s maximal gradient, min-
imal vessel diameter and change in the RV/FA pressure
ratio were made using a two-tailed t test. Statistical signif-
icance was set at p , 0.05.
RESULTS
Of 368 patients with a total of 752 stents implanted, 220
were recatheterized. Of those 220 patients, 103 underwent
stent redilation (76 patients were redilated once, 22 patients
twice and 5 patients three times). Indications for repeat
catheterization in the 220 patients included patients in the
initial part of the study protocol during our early experience
with stent implantation (generally one year after the initial
stent implant), patients who had doubled their body weight
since the initial stent implant and patients who developed
evidence of increased right heart pressures (clinically or
echocardiographically with estimation of RV pressure from
tricuspid regurgitation [TR] jet peak velocities). The pa-
tients’ median age was 9.9 years (range 0.5 to 39.8). The
male to female ratio was 1.5:1; their mean weight was 36 kg
(range 5.3 to 102). The mean follow-up duration was 3.8
years (range 0.1 to 10). The mean interval from stent
implantation to redilation was two years (range 0.1 to 7.5).
The mean duration from redilation to follow-up was two
years (range from 0.1 to 7.4). Indications for stent redilation
included somatic growth (n 5 67), serial dilation (n 5 27)
and development of neointimal proliferation and restenosis
(n 5 9). The overall mean vessel diameter increased from
8.8 to 12.8 mm (p , 0.003). For patients with branch
pulmonary stenosis (i.e., tetralogy of Fallot [TOF]/
pulmonary atresia [PA], congenital branch pulmonary ste-
nosis [CBPS], arterial switch operation [ASO]), the mean
arterial gradient decreased from 20 to 6 mm Hg (p ,
0.001), and the RV/FA ratio decreased from 0.5 to 0.39
(p , 0.001).
The 103 patients analyzed were classified into three
groups:
1) pulmonary artery stent group (n 5 94). They were
further classified into four subgroups (a–d).
a) status after repair of TOF and PA subgroup (n 5 72).
Of 142 patients with stents placed for TOF/PA who were
recatheterized, 72 were redilated (51%). The mean systolic
gradient at redilation decreased from 20 (range 0 to 70) to
6 mm Hg (range 0 to 40) (p , 0.001). The mean vessel
diameter increased from 9.4 (range 3 to 19) to 13.2 mm
(range 5 to 24) (p , 0.001). The mean RV/FA pressure
ratio decreased from 0.48 (range 0.2 to 1.1) to 0.4 (range 0.2
to 0.9) (p , 0.001).
b) CPBS subgroup (n 5 9). Of 23 patients with stents
placed for CPBS who were recatheterized, 9 were redilated
(39%). The mean systolic gradient at redilation decreased
from 19 (range 3 to 40) to 8 mm Hg (range 0 to 22) (p 5
0.004), and the mean vessel diameter increased from 8.3
(range 5 to 12) to 11.2 mm (range 8 to 16) (p , 0.001). The
mean RV/FA pressure ratio decreased from 0.59 (range 0.4
to 1.2) to 0.46 (range 0.3 to 0.9) (p 5 0.03).
c) Status after Fontan operation subgroup (n 5 6). Of 16
patients with stents placed in the Fontan operation sub-
group who were recatheterized, 6 were redilated (38%). The
mean systolic gradient at redilation decreased from 3 (range
0.5 to 7) to 0.5 mm Hg (range 0 to 2) (p 5 0.03). The mean
vessel diameter increased from 10.5 (range 7 to 13) to
14 mm (range 10 to 17) (p , 0.003). A comparison of the
RV/FA pressure ratio was not applicable for this group.
d) Status after ASO subgroup (n 5 7). Of 16 patients
with stents placed in this subgroup who were recatheterized,
7 were redilated (43%). The mean systolic gradient at
redilation decreased from 27 (range 9 to 40) to 7 mm Hg
(range 2 to 11) (p 5 0.001). The mean vessel diameter
increased from 8.0 (range 2 to 12) to 12.6 mm (range 8 to
16) (p 5 0.001). The mean RV/FA pressure ratio decreased
from 0.52 (range 0.3 to 0.6) to 0.35 (range 0.3 to 0.4) (p 5
0.004).
2) Iliofemoral vein occlusion group (n 5 6). Of 16
patients with stents placed for iliofemoral vein occlusion
who were recatheterized, 6 were redilated (38%). The mean
vessel diameter at redilation increased from 2.0 (range 0 to
6) to 6.3 mm (range 2 to 12) (p 5 0.04). Measurement of
the RV/FA pressure ratio and pressure gradient were not
applicable for this group.
3) Miscellaneous group (coarctation of the aorta, Blalock-
Taussig shunt and superior vena cava [SVC] conduit) (n 5
3). In the patient with coarctation of the aorta, the systolic
gradient at redilation decreased from 80 to 14 mm Hg, and
the vessel diameter increased from 3.6 to 7.8 mm. The
vessel diameter increased at redilation from 13 to 17 mm in
the patient with SVC conduit stenosis, and from 5 to 7 mm
Abbreviations and Acronyms
ASO 5 arterial switch operation
CBPS 5 congenital branch pulmonary stenosis
CHD 5 congenital heart disease
FA 5 femoral artery
IVC 5 inferior vena cava
PA 5 pulmonary atresia
RV 5 right ventricle or ventricular
SVC 5 superior vena cava
TOF 5 tetralogy of Fallot
TR 5 tricuspid regurgitation
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in the patient with Blalock-Taussig shunt stenosis. Mea-
surement of the RV/FA pressure ratio was not applicable for
this group.
Neointimal proliferation. Of the 220 patients who under-
went repeat catheterization, 208 had no significant neoin-
timal proliferation (mild in 8 patients). Significant neointi-
mal proliferation was present in four patients (1.8%),
moderate in two and severe in two. Those with moderate
neointimal proliferation were redilated, and those with
severe neointimal proliferation underwent additional stent
implantation. The neointimal thickness was reduced in all
patients after redilation, with or without additional stent
implantation.
Restenosis. Restenosis developed in 5 (2%) of 220 patients
who were recatheterized. Specific risk factors were identified
for the development of restenosis, which included:
c A lack of overlap in tandem stents (n 5 1). A patient with
CBPS developed restenosis in the right pulmonary artery
after minimal stent separation of 1 to 2 mm. The same
patient did not develop restenosis in the contralateral
pulmonary artery, which had 8 to 10 mm of stent overlap
(Fig. 1).
c Sharp angulation of the stent to the vessel wall (n 5 1). In
one of the early patients in our cohort, placement of a
stent with sharp angulation to the curvilinear pulmonary
artery wall resulted in development of restenosis at the
distal end of the stent. This probably occurred as a
reaction of the vessel wall to the sharp stent struts (Fig. 2).
c Overdilation of the stent (n 5 1) (Fig. 3).
c Stent implanted in the abnormal tissue (n 5 2). Two
patients with presumed abnormal tissue characteristics
also developed restenosis. One patient who had the ASO
and Lecompte maneuver performed developed severe
diffuse hypoplasia of both branch pulmonary arteries. At
the time of the initial stent implant after bilateral sequen-
tial stent implantation, the stents in the right pulmonary
artery had already “contracted down” (Figs. 4 and 5). At
follow-up, he had developed bilateral restenoses, which
were successfully redilated, with a reduction in the
RV/FA pressure ratio from 0.62 to 0.34 and an increase
in the stent’s vessel diameter by 20%. Another patient
with Williams syndrome with severe diffuse pulmonary
artery hypoplasia developed restenosis after redilation,
despite a 50% increase in the vessel diameter.
Complications. Of 103 patients who underwent stent
redilation, complications occurred in 4 (2%) of 135 proce-
dures. Complications included:
c Pulmonary edema (n 5 1). This patient with TOF and an
absent left pulmonary artery previously underwent stent
implantation in the right pulmonary artery. Secondary to
supra-systemic RV pressure redilation of two right pul-
Figure 1. Angiograms of the pulmonary arteries, delineating a lack of
sufficient stent overlap. a) Two stents in the right pulmonary artery nearly
became separated. b) Intimal build-up noted at the site of insufficient
overlap and not in the remainder of the stents.
Figure 2. Angiograms of the right pulmonary artery, delineating sharp
angulation (right anterior oblique and cranial projections). a) Initial
curvature of the vessel before stenting. b) Stenosis at recatheterization after
the initial stent implant. c) Restenting with several shorter overlapping
stents.
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monary artery stents and balloon dilation of five distal
pulmonary branches were performed, with a reduction in
the RV/FA ratio from 1 to 0.7.
c Hemoptysis (n 5 1). After TOF repair, hemoptysis
occurred after redilation of a right pulmonary artery stent;
the hemoptysis resolved without sequelae.
c Stent compression (n 5 2). Stent compression occurred
after redilation of the contralateral branch stent in a
patient who had TOF repair and in another patient after
PA/ventricular septal defect repair. The stent was re-
moved at the time of conduit replacement in the latter
patient. This contralateral stent compression complica-
tion occurred early in our experience; this complication is
now avoided by simultaneous bilateral balloon inflation of
branching stents.
In all stent redilation procedures, there were no transfu-
sions, stent embolizations, emergent operations or deaths.
DISCUSSION
Over the last decade, the application of endovascular stents
in patients with CHD has proven very successful. Stents
have been particularly effective in the treatment of postop-
erative pulmonary artery branch stenoses and systemic
venous stenoses, for which further surgical treatment is
limited. Isolated balloon angioplasty of arterial and venous
stenoses has been shown to be inadequate, with early
follow-up demonstrating restenosis rates as high as 40%
(12,13). Redilation of endovascular stents may be required
to accommodate the patient’s somatic growth (not previ-
ously described), for staged, serial “further” dilation to avoid
vessel overdilation during stent implant, for neointimal
proliferation or for the development of restenosis. Early
follow-up studies demonstrated very low rates of significant
stent neointimal proliferation and/or restenosis, occurring in
only 3% of patients, with a mean duration of follow-up of 13
months (11).
Restenosis. We defined restenosis as a reduction in the
stent lumen diameter less than the nominal adjacent vessel
diameter and/or the development of or increase in the
pressure gradient across the stent. However, it is important
to identify those cases where the stented vessel diameter has
remained the same since the initial implant and the adjacent
vessel to the stent has undergone further growth. This may
give the appearance of restenosis on the angiogram, but with
no change in the stent’s vessel diameter, it does not
Figure 3. Angiograms of the pulmonary arteries, delineating overdilation
of the right pulmonary artery at the initial stent implant. a) Stretched/
elongated right and left pulmonary arteries before stent placement. b)
Neointimal proliferation of the left pulmonary artery at the time of recath-
eterization. c) Angiogram of the left pulmonary artery after redilation.
Figure 4. Anteroposterior projection of the pulmonary arteries, delineating abnormal tissue characteristics. a) The branch pulmonary arteries after the initial
balloon dilation appear stretched and elongated. b) The proximal vessel is “contracted down” after placement of the distal stent. c) The proximal stent is
placed in the same setting.
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represent true restenosis. This is one of the primary reasons
for repeating catheterization one to three years after the
initial stent implant, so one can assess vessel growth
adjacent to the stent and the need for further stent dilation
to accommodate somatic growth.
Only one stent occlusion was found (0.5%) (left femoral
vein/inferior vena caval stenosis after a long-term indwelling
central line within the stent). Restenosis occurred in only
2% of our patients, slightly less than the rate found in
another study at early follow-up in a smaller cohort of
patients (11). In each case, specific risk factors were iden-
tified, including inadequate stent overlap, overdilation of the
stent and abnormal underlying vascular tissue. A lack of
overlap in tandem stents may result in movement of the
stents relative to each other, which may traumatize the
intervening vessel wall. Likewise, sharp angulation of the
end of a stent results in struts penetrating into the vessel
wall, which may act as a template for the development of
restenosis or neointimal growth.
The identification of these factors, which predispose to
stent restenosis, has enabled us to improve our technique
and results. Specifically, we ensure adequate stent overlap,
and, if necessary, we implant several short, overlapping
stents along the vessel curvature to allow better alignment
with the vessel wall. Although we have had limited experi-
ence with them, recently developed stents with increased
flexibility (Intratherapeautics stents, St. Paul, Minnesota)
may allow for better vessel–stent alignment. Modification of
stent technique, however, in those patients with intrinsically
abnormal vascular tissue is difficult, and restenosis in these
patients may be less indicative of stent failure, but an
unavoidable response of the underlying abnormal vascular
tissue.
Neointimal proliferation. One recent study using self-
expanding Wallstents in a small group (25 stents implanted
in a total of 22 procedures) reported an incidence of
neointimal proliferation of 28% (14). They defined neoin-
timal proliferation as neointimal growth .30% of the vessel
diameter, reporting its development in five pulmonary artery
stents, one left SVC stent and one modified Blalock-
Taussig shunt; one of the pulmonary artery stents was
totally occluded. These results are markedly different from
our experience using balloon-expandable (Palmaz) stents.
Even when we used our stricter definition of neointimal
proliferation, our patients developed significantly less neo-
intimal proliferation (4%). Avoidance of initial overdilation
of the stent appears to result in a reduction in the risk of
neointimal proliferation, and hopefully avoidance of aneu-
rysm formation and vessel perforation.
Somatic growth. Initially, there were concerns about the
potential for stent redilation to accommodate somatic
growth. Published animal studies by Grifka et al. (15) and
Morrow et al. (16) unequivocally demonstrated the poten-
tial to increase the diameter of previously implanted,
balloon-expandable stents using larger balloons to accom-
modate for somatic growth. We advocate staged, serial
further dilation of arterial and venous stents, rather than
attempting to gain a maximal vessel diameter at the initial
stent implant, because this appears to predispose the patient
to neointimal proliferation and restenosis and may increase
the risk of complications. There was no significant disparity
between the need for redilation between the groups, given
that somatic growth was common to all groups.
Study limitations. Although the results of this study are
encouraging, demonstrating improved hemodynamic data,
low rates of restenosis and neointimal proliferation at
intermediate-term follow-up, there are a number of study
limitations. This study group represents one center’s expe-
rience and may not mirror that of the general interventional
community. Catheterization data were based on retrospec-
tive analysis of the catheterization procedures. Also, we
defined neointimal proliferation as significant if it was
.1 mm on either side of the stent wall, an arbitrary measure
that may not be agreed upon by other institutions. Finally,
the mean follow-up period of our patients was 3.8 years
(range 0.1 to 10), which allows us to comment only on
intermediate-term outcomes.
Figure 5. Lateral projection of the same pulmonary arteries as in Figure 4. a) Again, the branch pulmonary arteries after the initial balloon dilation appear
stretched and elongated. b) The proximal vessel is “contracted down” after placement of the distal stent. c) The proximal stent is placed in the same setting.
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Conclusions. Redilation of endovascular stents for patients
with CHD is effective as late as 10 years after the initial
stent implant. The majority of patients will require stent
redilation to accommodate somatic growth. The risk of
significant neointimal proliferation (1.8%) and restenosis
(2%) is low and possibly avoidable, and this subset of
patients may require redilation. Modification of the stent
implantation technique, including avoidance of minimal
stent overlap, of sharp angulation of the stent to the vessel
wall and of overdilation, has reduced the incidence of
restenosis. Awareness of these factors and increased opera-
tor experience has resulted in a low complication rate over
the last decade. These data continue to advocate the use of
endovascular stent implantation as the treatment of choice
for both arterial and venous stenoses for many congenital
heart defects.
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